DSGN
Design Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.64
+3.20%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$10.39
From 52W high−33.25%
Volume359188.00
Market cap$665.87M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$10.39
From 52W high
−33.25%
Volume
359188.00
Market cap
$665.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.4x
P/E (TTM)
—
RSI (14)
39.3
MomentumView details →
1D Return
+3.20%
YTD Return
+15.57%
SummaryUpdated Jun 1, 2026
Design Therapeutics, Inc. (NASDAQ:DSGN) is a preclinical-stage biopharmaceutical company founded in 2017 and headquartered in Carlsbad, California. The company went public in March 2021 and focuses on developing innovative therapies for genetic diseases caused by nucleotide repeat expansions. Design Therapeutics has built a proprietary platform called GeneTAC to create small molecule drugs that can precisely modulate gene expression, targeting a class of previously undruggable genetic disorders that affect millions of patients worldwide.
Similar companies
Latest newsMore news →
Design Therapeutics, Inc. reported a net loss of $20.2 million for Q2 2026, with research and development expenses of $16.4 million and general and administrative expenses of $5.8 million.78d agoDesign Therapeutics initiated patient dosing in a Phase 1 multiple-ascending dose trial of DT-818 for myotonic dystrophy type-1.112d ago